ClinicalTrials.gg
CompletedNCT07073157Updated Aug 28, 2025

Effect of HRS-8427 for Injection on the Pharmacokinetics of Furosemide and Metformin in Healthy Subjects。

A Phase 1 interventional study of HRS-8427 injection plus furosemide and HRS-8427 injection plus metformin in Health Volunteer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-28.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The pharmacokinetics of HRS-8427 for injection on the transporter OAT1 substrate furosemide and the MATE1/METE2-K substrate metformin were evaluated in healthy subjects. The safety of HRS-8427 for injection was evaluated in combination with furosemide and metformin.

02

Conditions studied

  • Health Volunteer
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and female subjects aged from 18 to 45 years old (including 18 and 45 years old, subject to the time of signing the )
  2. Body weight ≥45 kg for female subjects and ≥50 kg for male subjects with (BMI) in the range of 19.0-26.0 kg/m2 (BMI = weight (kg)/height 2 (m2)), including boundary values
  3. Female subjects were not pregnant or lactating and had a negative pretrial pregnancy test. Male or female subjects agreed to use a highly effective method approved by the investigator as required by the investigator (see Appendix 13 to the protocol) for the duration of the trial, with no sperm/egg donation planned (from the time of informed consent until 3 months after the last dose).
  4. have understood the nature, significance, possible benefits, possible inconvenience and potential risks of the trial in detail before the trial, and voluntarily participate in the clinical trial, can communicate well with the investigators, comply with the requirements of the whole study, and sign the written informed consent

Exclusion criteria

Exclusion Criteria:

  1. Have a history of food or drug allergy
  2. previous or current diseases of the heart, liver, kidney, endocrine, digestive tract, immune system, respiratory system, musculoskeletal system, and nervous system
  3. Plasma concentrations of sodium, potassium, magnesium and calcium were lower than the normal range and serum creatinine was not in the normal range
  4. Patients with fasting blood glucose below the normal range or a history of hypoglycemia.
  5. Abnormal 12-lead and the investigator's judgment that the patient is not suitable for the study (including but not limited to > 450 ms, severe arrhythmia such as atrioventricular block of degree II or above)
  6. Laboratory tests (blood routine test, urine routine test, urine sediment test, blood biochemistry, coagulation function test, thyroid function test), physical examination, vital signs (temperature, blood pressure, pulse), abdominal ultrasound and chest X-ray results were judged by clinicians as abnormalities。
  7. Infectious disease tests ( antibody, surface antigen, anti- virus antibody, anti-treponema pallidum specific antibody) were positive。
  8. Patients who underwent major surgery within 3 months before screening; Or underwent surgery that may affect the in vivo course or safety evaluation of the study drug; Or planned to undergo surgery during the study period。
  9. Participants who had been enrolled in a drug clinical trial within 3 months before screening and had taken a trial drug, or who planned to participate in another clinical trial during the study period。
  10. Participants who had donated blood or had a blood loss of more than 300 mL or received a transfusion or blood product within 3 months before screening or were scheduled to donate blood during or within 1 month after the trial。
  11. Those who had a history of drug abuse within 3 months before screening, had a history of drug use, or had a positive screening test for drug abuse。
  12. The participant had any other factor that was deemed by the investigator to preclude participation in the trial
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    HRS-8427 injection plus furosemide

    Drug: HRS-8427 injection plus furosemide

  • Experimental
    HRS-8427 injection plus metformin

    Drug: HRS-8427 injection plus metformin

Interventions

  • DrugHRS-8427 injection plus furosemide

    Drug pages: HRS-8427 · Furosemide

    HRS-8427 injection plus furosemide

  • DrugHRS-8427 injection plus metformin

    HRS-8427 injection plus metformin

06

What researchers measure

Primary outcomes

  1. Cmax

    Time frame: The observation lasted until the 9th day

  2. AUC0-t

    Time frame: The observation lasted until the 9th day

  3. AUC0-∞

    Time frame: The observation lasted until the 9th day

  4. Tmax

    Time frame: The observation lasted until the 9th day

  5. t1/2

    Time frame: The observation lasted until the 9th day

  6. CL/F

    Time frame: The observation lasted until the 9th day

  7. Vz/F

    Time frame: The observation lasted until the 9th day

Secondary outcomes

  1. adverse events

    Time frame: The observation lasted until the 16th day

07

Study locations

1 site
  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian 350005, China
08

References and documents

Publications

  • Yin T, Qu B, Zhang Q, Xu S, Wu Y, Jiang H, Huang Y, Hu W. Pharmacokinetics, safety, and tolerability of HRS-8427, a novel anti-carbapenem-resistant cephalosporin, in healthy subjects. Antimicrob Agents Chemother. 2026 Apr;70(4):e0069425. doi: 10.1128/aac.00694-25. Epub 2026 Mar 3. PubMed 41773934 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2025 to primary completion in Aug 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2025
First posted
Jul 18, 2025
StartActual
Jul 15, 2025
Primary completionActual
Aug 15, 2025
CompletionActual
Aug 15, 2025
Last update
Aug 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07073157
Responsible party
Sponsor
First posted
Jul 18, 2025
Start date
Jul 15, 2025
Primary completion
Aug 15, 2025
Completion
Aug 15, 2025
Last update
Aug 28, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: HRS-8427 · Furosemide

Start the discussion